TheraRadar
← Back
Data updated: Mar 29, 2026

OSMOTICA PHARM US

CardiovascularNeurology
Pharma

OSMOTICA PHARM US is a pharmaceutical company focused on Cardiovascular, Neurology. Key products include RELEXXII.

2005
Since
9
Drugs
-
Trials
124
Approved (2yr)

Key Drugs

RELEXXII
methylphenidate hydrochloride
CNS
1 indications · 2022

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

VENLAFAXINE HYDROCHLORIDE 2026-01-30
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
METHYLPHENIDATE HYDROCHLORIDE 2026-01-15
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 50%
1 drugs
Neurology 50%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

GE HEALTHCARE specialty
Neurology, Cardiovascular
Novo Nordisk big-pharma
Cardiovascular, Neurology
LEDERLE big-pharma
Cardiovascular, Neurology
PAI HOLDINGS PHARM big-pharma
Neurology, Cardiovascular
VALIDUS PHARMS specialty
Cardiovascular, Neurology